Loading…
Compliance with guideline-directed basic pharmacotherapy and late adverse events in patients with stable coronary artery disease after isolated surgical revascularization
Abstract Background Long-term basic pharmacotherapy may have a major impact upon clinical course and survival in patients with stable coronary artery diseases (CAD) after isolated coronary artery bypass grafting (CABG). Purpose To determine the role of compliance with guideline-directed basic pharma...
Saved in:
| Published in: | European heart journal 2020-11, Vol.41 (Supplement_2) |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | |
| container_issue | Supplement_2 |
| container_start_page | |
| container_title | European heart journal |
| container_volume | 41 |
| creator | Yepanchintseva, O Mikhaliev, K Shklianka, I Zharinov, O Todurov, B |
| description | Abstract
Background
Long-term basic pharmacotherapy may have a major impact upon clinical course and survival in patients with stable coronary artery diseases (CAD) after isolated coronary artery bypass grafting (CABG).
Purpose
To determine the role of compliance with guideline-directed basic pharmacotherapy in the prevention of late major adverse clinical events (MAEs) in patients with stable CAD after isolated CABG at 3-year follow-up.
Methods
A single-centre study included 576 patients with stable CAD, consecutively enrolled for isolated CABG during the period 2011–2017. Follow-up median was 34 months (interquartile range 13–60 months). Two (0.3%) patients died early after CABG, thus 574 (99.7%) patients were followed post-discharge. At 3-year follow-up, data on MAEs were available in 251 patients, mean age (61±9) years, 218 (86.9%) males. Among them, MAEs occurred in 55 (21.9%) cases.
Results
Basic CAD pharmacotherapy after CABG was comparable in MAEs vs. no-MAEs groups, with the vast majority of patients receiving guideline-recommended therapy at discharge, namely angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-II receptors blockers (ARBs) (79.6% vs. 88.8%, respectively; p=0.109), statins (98.1% vs. 99.0%, respectively; p=0.619) and antiplatelet drugs (98.1% vs. 99.5%, respectively; p=0.327). At 3-year follow-up, MAEs group, as opposed to no-MAEs group, was characterized by the lower usage of ACEI/ARBs (68.5% vs. 87.2%, respectively; p=0.001) and statins (59.3% vs. 86.7%, respectively; p |
| doi_str_mv | 10.1093/ehjci/ehaa946.1459 |
| format | article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ehjci_ehaa946_1459</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ehjci/ehaa946.1459</oup_id><sourcerecordid>10.1093/ehjci/ehaa946.1459</sourcerecordid><originalsourceid>FETCH-LOGICAL-c819-4b4633eeda0c69fefef8662090159c2c33371348aae4586d672770ab7570e83c3</originalsourceid><addsrcrecordid>eNqNkE1qwzAQhUVpoWnaC3SlCziVLFu2liX0DwLdZNGdGUvjWMGxjKSktEfqKaukOUAZmDcD8x7DR8g9ZwvOlHjAfqtt6gCqkAtelOqCzHiZ55mSRXlJZoyrMpOy_rgmNyFsGWO15HJGfpZuNw0WRo3008aebvbW4GBHzIz1qCMa2kKwmk49-B1oF3v0MH1RGA0dICIFc0AfkOIBxxioHekE0Z7mU2KI0A5ItfNuBJ-MPmISYwNCskGXVmqDO4YZGvZ-YzUM1OMBgt4P4O13ynPjLbnqYAh4d9Y5WT8_rZev2er95W35uMp0zVVWtIUUAtEA01J1mKqWMmeK8VLpXAshKi6KGgCLspZGVnlVMWirsmJYCy3mJP-L1d6F4LFrJm936fGGs-YIuznBbs6wmyPsZMr-TG4__ef-F-D1ifw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Compliance with guideline-directed basic pharmacotherapy and late adverse events in patients with stable coronary artery disease after isolated surgical revascularization</title><source>Oxford Journals Online</source><creator>Yepanchintseva, O ; Mikhaliev, K ; Shklianka, I ; Zharinov, O ; Todurov, B</creator><creatorcontrib>Yepanchintseva, O ; Mikhaliev, K ; Shklianka, I ; Zharinov, O ; Todurov, B</creatorcontrib><description>Abstract
Background
Long-term basic pharmacotherapy may have a major impact upon clinical course and survival in patients with stable coronary artery diseases (CAD) after isolated coronary artery bypass grafting (CABG).
Purpose
To determine the role of compliance with guideline-directed basic pharmacotherapy in the prevention of late major adverse clinical events (MAEs) in patients with stable CAD after isolated CABG at 3-year follow-up.
Methods
A single-centre study included 576 patients with stable CAD, consecutively enrolled for isolated CABG during the period 2011–2017. Follow-up median was 34 months (interquartile range 13–60 months). Two (0.3%) patients died early after CABG, thus 574 (99.7%) patients were followed post-discharge. At 3-year follow-up, data on MAEs were available in 251 patients, mean age (61±9) years, 218 (86.9%) males. Among them, MAEs occurred in 55 (21.9%) cases.
Results
Basic CAD pharmacotherapy after CABG was comparable in MAEs vs. no-MAEs groups, with the vast majority of patients receiving guideline-recommended therapy at discharge, namely angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-II receptors blockers (ARBs) (79.6% vs. 88.8%, respectively; p=0.109), statins (98.1% vs. 99.0%, respectively; p=0.619) and antiplatelet drugs (98.1% vs. 99.5%, respectively; p=0.327). At 3-year follow-up, MAEs group, as opposed to no-MAEs group, was characterized by the lower usage of ACEI/ARBs (68.5% vs. 87.2%, respectively; p=0.001) and statins (59.3% vs. 86.7%, respectively; p<0.001), as well as triple basic CAD therapy (ACEI or ARBs/statins/antiplatelet drugs: 35.2% vs. 70.4%, respectively; p<0.001).
Conclusion
At 3-year follow-up, MAEs in patients with stable CAD after isolated CABG were associated with more frequent discontinuation of previously prescribed guideline-directed basic pharmacotherapy, namely ACEI/ARBs and statins, as well as triple basic CAD therapy.
Funding Acknowledgement
Type of funding source: None</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/ehjci/ehaa946.1459</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2020-11, Vol.41 (Supplement_2)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com. 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids></links><search><creatorcontrib>Yepanchintseva, O</creatorcontrib><creatorcontrib>Mikhaliev, K</creatorcontrib><creatorcontrib>Shklianka, I</creatorcontrib><creatorcontrib>Zharinov, O</creatorcontrib><creatorcontrib>Todurov, B</creatorcontrib><title>Compliance with guideline-directed basic pharmacotherapy and late adverse events in patients with stable coronary artery disease after isolated surgical revascularization</title><title>European heart journal</title><description>Abstract
Background
Long-term basic pharmacotherapy may have a major impact upon clinical course and survival in patients with stable coronary artery diseases (CAD) after isolated coronary artery bypass grafting (CABG).
Purpose
To determine the role of compliance with guideline-directed basic pharmacotherapy in the prevention of late major adverse clinical events (MAEs) in patients with stable CAD after isolated CABG at 3-year follow-up.
Methods
A single-centre study included 576 patients with stable CAD, consecutively enrolled for isolated CABG during the period 2011–2017. Follow-up median was 34 months (interquartile range 13–60 months). Two (0.3%) patients died early after CABG, thus 574 (99.7%) patients were followed post-discharge. At 3-year follow-up, data on MAEs were available in 251 patients, mean age (61±9) years, 218 (86.9%) males. Among them, MAEs occurred in 55 (21.9%) cases.
Results
Basic CAD pharmacotherapy after CABG was comparable in MAEs vs. no-MAEs groups, with the vast majority of patients receiving guideline-recommended therapy at discharge, namely angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-II receptors blockers (ARBs) (79.6% vs. 88.8%, respectively; p=0.109), statins (98.1% vs. 99.0%, respectively; p=0.619) and antiplatelet drugs (98.1% vs. 99.5%, respectively; p=0.327). At 3-year follow-up, MAEs group, as opposed to no-MAEs group, was characterized by the lower usage of ACEI/ARBs (68.5% vs. 87.2%, respectively; p=0.001) and statins (59.3% vs. 86.7%, respectively; p<0.001), as well as triple basic CAD therapy (ACEI or ARBs/statins/antiplatelet drugs: 35.2% vs. 70.4%, respectively; p<0.001).
Conclusion
At 3-year follow-up, MAEs in patients with stable CAD after isolated CABG were associated with more frequent discontinuation of previously prescribed guideline-directed basic pharmacotherapy, namely ACEI/ARBs and statins, as well as triple basic CAD therapy.
Funding Acknowledgement
Type of funding source: None</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqNkE1qwzAQhUVpoWnaC3SlCziVLFu2liX0DwLdZNGdGUvjWMGxjKSktEfqKaukOUAZmDcD8x7DR8g9ZwvOlHjAfqtt6gCqkAtelOqCzHiZ55mSRXlJZoyrMpOy_rgmNyFsGWO15HJGfpZuNw0WRo3008aebvbW4GBHzIz1qCMa2kKwmk49-B1oF3v0MH1RGA0dICIFc0AfkOIBxxioHekE0Z7mU2KI0A5ItfNuBJ-MPmISYwNCskGXVmqDO4YZGvZ-YzUM1OMBgt4P4O13ynPjLbnqYAh4d9Y5WT8_rZev2er95W35uMp0zVVWtIUUAtEA01J1mKqWMmeK8VLpXAshKi6KGgCLspZGVnlVMWirsmJYCy3mJP-L1d6F4LFrJm936fGGs-YIuznBbs6wmyPsZMr-TG4__ef-F-D1ifw</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Yepanchintseva, O</creator><creator>Mikhaliev, K</creator><creator>Shklianka, I</creator><creator>Zharinov, O</creator><creator>Todurov, B</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20201101</creationdate><title>Compliance with guideline-directed basic pharmacotherapy and late adverse events in patients with stable coronary artery disease after isolated surgical revascularization</title><author>Yepanchintseva, O ; Mikhaliev, K ; Shklianka, I ; Zharinov, O ; Todurov, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c819-4b4633eeda0c69fefef8662090159c2c33371348aae4586d672770ab7570e83c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yepanchintseva, O</creatorcontrib><creatorcontrib>Mikhaliev, K</creatorcontrib><creatorcontrib>Shklianka, I</creatorcontrib><creatorcontrib>Zharinov, O</creatorcontrib><creatorcontrib>Todurov, B</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yepanchintseva, O</au><au>Mikhaliev, K</au><au>Shklianka, I</au><au>Zharinov, O</au><au>Todurov, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Compliance with guideline-directed basic pharmacotherapy and late adverse events in patients with stable coronary artery disease after isolated surgical revascularization</atitle><jtitle>European heart journal</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>41</volume><issue>Supplement_2</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract
Background
Long-term basic pharmacotherapy may have a major impact upon clinical course and survival in patients with stable coronary artery diseases (CAD) after isolated coronary artery bypass grafting (CABG).
Purpose
To determine the role of compliance with guideline-directed basic pharmacotherapy in the prevention of late major adverse clinical events (MAEs) in patients with stable CAD after isolated CABG at 3-year follow-up.
Methods
A single-centre study included 576 patients with stable CAD, consecutively enrolled for isolated CABG during the period 2011–2017. Follow-up median was 34 months (interquartile range 13–60 months). Two (0.3%) patients died early after CABG, thus 574 (99.7%) patients were followed post-discharge. At 3-year follow-up, data on MAEs were available in 251 patients, mean age (61±9) years, 218 (86.9%) males. Among them, MAEs occurred in 55 (21.9%) cases.
Results
Basic CAD pharmacotherapy after CABG was comparable in MAEs vs. no-MAEs groups, with the vast majority of patients receiving guideline-recommended therapy at discharge, namely angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-II receptors blockers (ARBs) (79.6% vs. 88.8%, respectively; p=0.109), statins (98.1% vs. 99.0%, respectively; p=0.619) and antiplatelet drugs (98.1% vs. 99.5%, respectively; p=0.327). At 3-year follow-up, MAEs group, as opposed to no-MAEs group, was characterized by the lower usage of ACEI/ARBs (68.5% vs. 87.2%, respectively; p=0.001) and statins (59.3% vs. 86.7%, respectively; p<0.001), as well as triple basic CAD therapy (ACEI or ARBs/statins/antiplatelet drugs: 35.2% vs. 70.4%, respectively; p<0.001).
Conclusion
At 3-year follow-up, MAEs in patients with stable CAD after isolated CABG were associated with more frequent discontinuation of previously prescribed guideline-directed basic pharmacotherapy, namely ACEI/ARBs and statins, as well as triple basic CAD therapy.
Funding Acknowledgement
Type of funding source: None</abstract><pub>Oxford University Press</pub><doi>10.1093/ehjci/ehaa946.1459</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 2020-11, Vol.41 (Supplement_2) |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_ehjci_ehaa946_1459 |
| source | Oxford Journals Online |
| title | Compliance with guideline-directed basic pharmacotherapy and late adverse events in patients with stable coronary artery disease after isolated surgical revascularization |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T23%3A22%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Compliance%20with%20guideline-directed%20basic%20pharmacotherapy%20and%20late%20adverse%20events%20in%20patients%20with%20stable%20coronary%20artery%20disease%20after%20isolated%20surgical%20revascularization&rft.jtitle=European%20heart%20journal&rft.au=Yepanchintseva,%20O&rft.date=2020-11-01&rft.volume=41&rft.issue=Supplement_2&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/ehjci/ehaa946.1459&rft_dat=%3Coup_cross%3E10.1093/ehjci/ehaa946.1459%3C/oup_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c819-4b4633eeda0c69fefef8662090159c2c33371348aae4586d672770ab7570e83c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ehjci/ehaa946.1459&rfr_iscdi=true |